In May 2025, the world celebrated the success of KJ, an infant who was treated with the world’s first personalized CRISPR gene editing therapy. KJ was born with severe carbamoyl phosphate synthetase 1 ...
A recent study utilizing cryo-EM advances our understanding of how bacterial immune systems function and reveals new aspects ...
Gene editing is a numbers game. For any genetic tweaks to have notable impact, a sufficient number of targeted cells need to have the disease-causing gene deleted or replaced. Despite a growing ...
Gene editing is growing up. Ten years after Science magazine named CRISPR its 2015 “Breakthrough of the Year,” this revolutionary gene editing technology has become a workhorse of modern biology. In ...
CRISPR Therapeutics (NASDAQ:CRSP) is one of the best stocks for 20 years. On February 12, CRISPR Therapeutics announced its financial results for 2025, highlighting a period of significant commercial ...
For many people interested in genome engineering, the era “before CRISPR” has faded into the deepest recesses of the mind, like a lost period of antiquity, even though it only entered the biotech ...
CRISPR Therapeutics' recent in vivo CTX310 data validates its technology, marking a fundamental shift and supporting a rating upgrade from Sell to Hold. CASGEVY sales are growing but remain ...
Researchers are applying CRISPR-Cas9 as a stoichiometric binding tool to improve NGS library normalization. The non-destructive strategy reduces variability, fits existing workflows, and may enhance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results